1. Scrip
  2. >>Business
  3. >>Deals

Black Diamond Gets The Gift Of Time In License Pact With Servier

 
• By Joseph Haas

Servier takes a Phase I rationally designed cancer candidate for $70m up front, while Black Diamond will wait on more mature data for its Phase II lead candidate in lung cancer.

dealmaking
Black Diamond out-licenses Phase I cancer candidate to Servier • Source: Shutterstock

A few months after restructuring to conserve cash and put primary focus on its lead candidate BDTX-1535 in first-line non-small cell lung cancer, Black Diamond Therapeutics found a lifeline in Servier, which is licensing a de-emphasized Black Diamond candidate for $70m up front. With the money, Black Diamond can push back a planned Phase II readout of BDTX-1535 to when it has a better chance of showing progression-free survival (PFS) data.

Key Takeaways
  • Black Diamond gets $70m up front from Servier for a de-emphasized lung cancer candidate, giving it expanded financial runway.
  • With the cash, the firm will push back its planned Phase II readout for lead candidate BDTX-1535 in NSCLC, hoping to present progression-free survival data later in 2025

Black Diamond announced the deal on 19 March, under terms that will immediately confer BDTX-4933, which targets RAF and RAS mutations in solid tumors including NSCLC, to Servier for global development and potential commercialization

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.